SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-3.13%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$532M
AUM Growth
+$532M
(-6.9%)
Cap. Flow
-$51.8M
Cap. Flow
% of AUM
-9.75%
Top 10 Holdings %
Top 10 Hldgs %
60.26%
Holding
28
New
1
Increased
10
Reduced
13
Closed
2
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$10.6M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$5.93M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$4.79M |
| 4 |
Abbott
ABT
|
$3.99M |
| 5 |
Elevance Health
ELV
|
$2.58M |
Top Sells
| 1 |
Biogen
BIIB
|
$21.1M |
| 2 |
Exelixis
EXEL
|
$16.3M |
| 3 |
Eli Lilly
LLY
|
$11.6M |
| 4 |
Bristol-Myers Squibb
BMY
|
$9.29M |
| 5 |
Baxter International
BAX
|
$5.6M |
Sector Composition
| 1 | Healthcare | 98.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$659B
| $49.1M | 9.23% |
667,050
-157,400
| -19% | -$11.6M |
|
|
2
Baxter International
BAX
$12.4B
| $42.2M | 7.95% |
952,833
-126,400
| -12% | -$5.6M |
|
|
3
Abbott
ABT
$229B
| $37.5M | 7.06% |
976,590
+104,000
| +12% | +$3.99M |
|
4
Revvity
RVTY
$10.1B
| $32.5M | 6.12% |
623,408
+7,980
| +1% | +$416K |
|
5
Ironwood Pharmaceuticals
IRWD
$213M
| $30.2M | 5.67% |
1,972,678
+12,130
| +0.6% | +$185K |
|
6
Boston Scientific
BSX
$158B
| $27.2M | 5.11% |
1,255,580
+700
| +0.1% | +$15.1K |
|
|
7
Bristol-Myers Squibb
BMY
$96.4B
| $26.3M | 4.94% |
449,290
-158,900
| -26% | -$9.29M |
|
8
Gilead Sciences
GILD
$140B
| $25.7M | 4.84% |
359,290
-5,700
| -2% | -$408K |
|
|
SHPG
9
DELISTED
Shire pic
SHPG
| $25M | 4.71% |
146,961
+62,500
| +74% | +$10.6M |
|
|
10
Vertex Pharmaceuticals
VRTX
$103B
| $24.6M | 4.63% |
333,950
+65,070
| +24% | +$4.79M |
|
11
Integra LifeSciences
IART
$1.18B
| $24.1M | 4.54% |
281,207
-25,000
| -8% | -$2.14M |
|
12
Masimo
MASI
$7.49B
| $21.1M | 3.97% |
313,004
-43,219
| -12% | -$2.91M |
|
13
Bio-Rad Laboratories Class A
BIO
$7.85B
| $20.8M | 3.91% |
114,042
-18,542
| -14% | -$3.38M |
|
|
14
Elevance Health
ELV
$72.3B
| $20.2M | 3.81% |
140,810
+17,960
| +15% | +$2.58M |
|
15
Merck
MRK
$212B
| $16.7M | 3.14% |
283,410
-34,600
| -11% | -$2.04M |
|
16
McKesson
MCK
$86B
| $16.2M | 3.04% |
115,200
-16,460
| -13% | -$2.31M |
|
|
PDCO
17
DELISTED
Patterson Companies, Inc.
PDCO
| $15.8M | 2.98% |
386,232
+40,440
| +12% | +$1.66M |
|
|
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $12.9M | 2.42% |
855,265
-103,614
| -11% | -$1.56M |
|
19
Cigna
CI
$80.3B
| $12.7M | 2.39% |
95,270
-16,800
| -15% | -$2.24M |
|
20
United Therapeutics
UTHR
$18.5B
| $9.75M | 1.83% |
67,974
-15,500
| -19% | -$2.22M |
|
|
LPNT
21
DELISTED
LifePoint Health, Inc.
LPNT
| $9.36M | 1.76% |
164,714
| – | – |
|
|
22
Exelixis
EXEL
$9.92B
| $7.76M | 1.46% |
520,091
-1,090,400
| -68% | -$16.3M |
|
23
Owens & Minor
OMI
$400M
| $7.56M | 1.42% |
214,172
+3,000
| +1% | +$106K |
|
|
IPXL
24
DELISTED
Impax Laboratories, Inc.
IPXL
| $6.61M | 1.24% |
499,153
+89,189
| +22% | +$1.18M |
|
|
ALXN
25
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $5.93M | 1.12% |
+48,500
| New | +$5.93M |
|